Retatrutide ("Reta") News: Trial Results, FDA Timeline and Why You Can't Get It Yet

Retatrutide, nicknamed "reta" online, is the weight-loss medicine everyone seems to be talking about. It's an experimental once-weekly injection from Eli Lilly, the company behind Mounjaro and Zepbound, and its clinical trial results have been the strongest seen so far for an obesity drug.

The short answer: retatrutide is not FDA-approved, and it isn't available from any pharmacy or telehealth provider. Lilly plans to ask the FDA for approval in early 2027, so it could be 2027 or later before doctors can prescribe it. Until then, the only legitimate way to take it is in a clinical trial.

That gap is why "reta" keeps making headlines. Unapproved versions are being sold online, and regulators and doctors are worried. Here's what the research shows, what the news means, and what you can do in the meantime.

The latest retatrutide news

Retatrutide trial results (TRIUMPH)

Lilly is testing retatrutide in a large set of Phase 3 studies called TRIUMPH. Here are the results announced so far:

• December 2025: The first Phase 3 study, in adults with obesity and knee osteoarthritis, showed weight loss and relief of knee pain.
• May 2026, TRIUMPH-1: The main obesity study enrolled 2,339 adults without diabetes. After 80 weeks, average weight loss was 19.0% at the 4 mg dose, 25.9% at 9 mg and 28.3% at 12 mg. People on 12 mg who continued to 104 weeks lost an average of 30.3%.
• July 2026, TRIUMPH-2 and TRIUMPH-3: In adults with type 2 diabetes, average weight loss reached 20.8% at 80 weeks, versus 4.0% with placebo, and A1C dropped by about 1.5 points. In adults with severe obesity and heart disease, average weight loss reached 22.6%, versus 3.2% with placebo.
• Fall 2026: Detailed TRIUMPH-2 results were presented at the European diabetes meeting (EASD) and published in The Lancet.

The most common side effects were digestive: nausea, diarrhea, constipation and vomiting, and they were more common at higher doses. Depending on the study and dose, roughly 4% to 13% of people stopped treatment because of side effects, compared with about 5% on placebo.

Sources: Eli Lilly, July 2026; AJMC on TRIUMPH-1; Drug Topics on TRIUMPH-2, October 2026

When could retatrutide be FDA-approved?

Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027. An FDA review usually takes about a year, so approval would most likely come in late 2027 or 2028. That timing isn't guaranteed. There is also an ongoing legal question about whether the FDA will classify retatrutide as a biologic, which could affect how it's reviewed.

Source: Eli Lilly, July 2026

The safety headlines

Most of the recent news is about unapproved "reta" sold outside of trials:

• In October 2026, CBS News reported two deaths submitted to the FDA's adverse event system in which black-market retatrutide was listed as a suspect product. The reports haven't been verified and don't prove the drug caused the deaths, but Lilly said both people had been taking black-market retatrutide.
• Poison control centers logged 862 retatrutide exposures from July to September 2026, up from 460 in the previous three months.
• A study in JAMA Network Open reviewed thousands of Reddit posts from people using unapproved retatrutide and found 129 different side effects reported. The researchers noted they couldn't verify what was actually in the products people used.

Sources: CBS News, October 2026; UNILAD summary of the JAMA Network Open study, October 2026

Retatrutide vs. semaglutide and tirzepatide

All three medicines work by mimicking hormones your gut releases after you eat. The difference is how many of those hormone signals each one targets:

Medicine	Hormone signals it targets	Status
Semaglutide	GLP-1	FDA-approved brands available; compounded versions prescribed by providers
Tirzepatide	GLP-1 and GIP	FDA-approved brands available; compounded versions prescribed by providers
Retatrutide	GLP-1, GIP and glucagon	Investigational; available only in clinical trials

GLP-1 and GIP help reduce appetite and support blood sugar control. Retatrutide adds glucagon, a hormone researchers think may increase the energy your body burns and help reduce liver fat. That third target is why it's often called a "triple agonist."

For context, the main trials behind the FDA-approved versions of semaglutide and tirzepatide reported average weight loss of about 15% and up to about 21%, respectively, over roughly 16 to 17 months. Trials differ in length, doses and the people enrolled, so these numbers can't be compared directly with retatrutide's results. Compounded semaglutide and tirzepatide are not FDA-approved and were not the medicines studied in those trials.

Can you get retatrutide now?

No, not legally, outside a clinical trial. Here's why the "reta" you see advertised online isn't a safe shortcut:

• It can't be legally compounded. Licensed compounding pharmacies can only work with ingredients that meet specific FDA rules. Retatrutide isn't part of any approved drug and isn't on the lists of substances pharmacies are allowed to compound, so no legitimate pharmacy or telehealth provider can prescribe it.
• "Research use only" isn't a loophole. Vials sold online as research peptides are labeled "not for human use." They aren't made under pharmacy standards, and no one checks what's inside. Lilly says it has found products with too much, too little or the wrong active ingredient, and it is suing sellers.
• The risks are real. As the news above shows, poison control calls about retatrutide are rising quickly, and deaths involving black-market products have been reported to the FDA.

At VEVArx, we only offer treatments prescribed by licensed providers and prepared by licensed 503A compounding pharmacies. We don't offer retatrutide, and we won't until it's FDA-approved and legally available. (Related: Can you buy tirzepatide online legally?)

Will retatrutide be a biologic? Why it matters

One of the less-talked-about retatrutide stories is a legal fight over how the FDA will classify it, and the answer could shape how people get it for years.

Lilly wants retatrutide treated as a biologic, the category for protein-based medicines, and is preparing that type of application. The FDA disagreed. Under its rules, a protein needs more than 40 amino acids to count as a biologic, and retatrutide falls just short. A court sided with the FDA on that rule but sent one question back to the agency: whether retatrutide is otherwise "analogous to a protein." Lilly has appealed. As of October 2026, the question is still open.

Here's why the outcome matters:

• If it's a biologic, it could never be compounded, not even during a shortage. Biologics fall outside the rules that allow pharmacies to compound medications. Lilly would also get 12 years before lower-cost competitors could launch.
• If it's regulated as a standard drug, compounding would still be off-limits at first. After approval, though, it could become eligible for compounding during an official FDA shortage, the way semaglutide and tirzepatide did. Competitors could launch after 5 years.

Either way, nothing changes today: retatrutide can't be legally compounded right now. The biologic question decides whether a compounded version could ever exist.

Source: AJMC, "5 Things to Know if Retatrutide Is Classified as a Biologic" (October 2026)

What to do while you wait for retatrutide

If retatrutide caught your attention because you're ready to get serious about weight loss, you don't have to wait for it. GLP-1 medications that are available today, such as semaglutide and tirzepatide, can be prescribed after a medical evaluation.

A few tips for getting started safely:

• Start with a licensed provider. A real medical evaluation checks whether a medication is right for you, your health history and any medicines you already take.
• Use a licensed pharmacy. Ask where your medication is made. Legitimate providers can tell you which licensed pharmacy prepares it.
• Skip anything sold "for research." If a site doesn't require a prescription, it isn't a medical service.
• Ask about the future. If retatrutide is approved, your provider can help you decide whether switching makes sense. (See also: Can you switch from semaglutide to tirzepatide?)

VEVArx offers provider-prescribed compounded semaglutide and compounded tirzepatide, 100% online. A licensed provider reviews your health history and decides whether treatment is appropriate. Compounded medications are not FDA-approved. See if tirzepatide may be right for you →

FAQ

Sources

• Eli Lilly: retatrutide successful in two additional Phase 3 obesity trials (July 23, 2026)
• AJMC: Retatrutide achieves up to 30.3% average weight loss in Phase 3 TRIUMPH-1
• Drug Topics: Retatrutide delivers 20.8% weight loss in adults with type 2 diabetes (Oct 9, 2026)
• CBS News: Two deaths reported to the FDA. Is bootleg "reta" to blame? (Oct 13, 2026)
• AJMC: 5 things to know if retatrutide is classified as a biologic (Oct 7, 2026)
• Drugs.com: Retatrutide FDA approval status
• UNILAD summary of the JAMA Network Open Reddit study (Oct 15, 2026)

Related guides

• Best tirzepatide providers online
• Best weight-loss injections compared
• Can you take semaglutide and tirzepatide together?

This article is for general information and isn't medical advice. Talk with a licensed healthcare provider before starting or changing any medication.